How SwishX Is Fixing Messy Back Office Sales Workflows For Pharma Companies With AI

SwishX, a startup co-founded by Dushyant Sapre, a former Google Cloud executive, is disrupting the messy back-office sales workflows of pharmaceutical companies through AI. After raising $4.5 million in early 2024, the company shuttered its initial device leasing service and pivoted to develop an agentic AI platform tailored for pharma and medtech businesses.

SwishX aims to become the software layer powering commercial operations in the pharmaceutical industry, starting with sales, distribution, hospital contracts, and government tenders.

The founders recognized that while enterprise device leasing had potential, it lacked differentiation. As their customer base grew, they discovered a significant portion of their clients were pharmaceutical companies seeking to automate workflows. This coincided with the rise of generative AI, leading the founders to pivot towards vertical AI, focusing on deeply specialized industry-specific workflows.

SwishX claims to have already achieved $1 million in annual recurring revenue (ARR) and aims to reach $5 million in contracted ARR with over 100 enterprise customers by the end of FY27.

SwishX's platform comprises four products: Tender IQ, Contract IQ, Marketing IQ, and Channel IQ. Tender IQ automates the bid preparation process for public healthcare systems, Contract IQ streamlines negotiations, approvals, and contract execution between pharma companies and hospitals, Marketing IQ converts product literature into AI-generated short-form video content for pharmaceutical marketing teams, and Channel IQ optimizes interactions with pharmacy networks in emerging markets.

SwishX leverages Anthropic's large language models and specialized offerings for its AI stack, but the founders believe their true advantage lies in their deep understanding of pharmaceutical workflows, which involve multiple approvals across various teams. By building these industry-specific workflows, SwishX is poised to address the untapped potential of the pharma sector in India and other emerging markets, where many companies still rely on outdated spreadsheets, fragmented systems, and legacy software.